A Study of Mircera (C.E.R.A.) in Patients With Pre-Dialysis Chronic Renal Anemia
Status:
Completed
Trial end date:
2012-11-30
Target enrollment:
Participant gender:
Summary
This single arm, open label, multicenter study will evaluate the safety and change in
hemoglobin levels of Mircera (C.E.R.A.; methoxy polyethylene glycol-epoetin beta) in patients
with chronic renal anemia who are not on dialysis. Patients will receive as a recommended
starting dose 1.2 micrograms of Mircera subcutaneously every 4 weeks. The starting dose is
dependent on the patient's weight. Dose adjustment may be required due to inadequate or
excessive treatment response. The anticipated time on study treatment is 28 weeks.